Japan to approve Remdesivir for coronavirus treatment this May
|Canada says one million masks from China not useable|
|HUFO presents 10,000 face masks to Thai people|
|Top coronavirus drugs and vaccines in development|
This supplied file photo shows anti-viral drug Remdesivir. Source: Kyodo
"The pharmaceutical approval (of remdesivir) will be possible shortly," Abe told a parliamentary session.
Remdesivir has been developed by US biopharmaceutical company Gilead Sciences Inc. as a possible treatment for Ebola.
A clinical test conducted by an international team on patients with severe COVID-19 symptoms will conclude this month.
The New England Journal of Medicine recently published a study showing the drug's effectiveness in nearly 70 per cent of 53 coronavirus patients with severe symptoms, while it caused serious side-effects, such as deterioration of kidney function, in a quarter of them.
A spokesperson of the Japan unit of Gilead Sciences said, "We are currently conducting clinical tests and are focused on confirming the drug's efficacy and safety."
Once an application by Gilead Sciences is made, the Japanese government is set to fast-track its approval. This streamlining of the process -- which involves postponing reports on domestic clinical tests to a later date -- is available on condition that the drug has been approved in another country.
In Japan, the anti-influenza drug Avigan is also going through clinical tests on COVID-19 patients, which will last through June. A scientific study in China has shown its efficacy in treating the disease.
The Japanese government has requested Fujifilm Toyama Chemical Co., a group firm of Fujifilm Holdings Corp., to boost production of Avigan, also known as favipiravir. As it is feared to cause birth defects, it cannot be administered to expecting mothers or those who may become pregnant.
Also Monday, Shionogi & Co. said it will develop a vaccine for the novel coronavirus, aiming to start clinical trials this year.
The Japanese company has decided to develop a recombinant protein vaccine for the virus that causes COVID-19 through its subsidiary UMN Pharma Inc., while also seeking to discover therapeutic drugs for the disease. Shionogi said it is looking to offer the vaccine for 10 million people.
The company is coordinating its plans with relevant parties including the Ministry of Health, Labor and Welfare./.
|Israeli Embassy donates one ton of rice to the needy of Hanoi |
Israeli Embassy donates ton of rice to those in Vietnamese capital who lost jobs due to coronavirus outbreak.
|US Secretary of State accuses China of pushing territorial ambitions during pandemic |
US Secretary of State Mike Pompeo in the online Special ASEAN-US Foreign Ministers' Meeting on COVID-19 warned China against taking advantage of the coronavirus pandemic ...
|ChildFund Vietnam supports over 27,000 children and families in response to COVID-19 pandemic |
ChildFund supports the Government in Vietnam’s approach and believes in the strength made of both the whole society and the government relevant to the response ...